Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Abstract Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to delay neurologic progression in ATTR...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Nicholas Streicher, Leslie Amass, Rong Wang, Jennifer M. Stephens, Traci LeMasters, Rutika Raina, Emma Merrill, Farooq H. Sheikh
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2024-03-01
Edice:	Cardiology and Therapy
Témata:	ATTR amyloidosis ATTR cardiomyopathy ATTR polyneuropathy Real-world Tafamidis
On-line přístup:	https://doi.org/10.1007/s40119-024-00362-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!